Freddy Ricardo Ygnacio

Mr. Freddy Ricardo Ygnacio

Inmunología, Farvet (Peru), Chincha Alta, Ica, Peru
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Anales de la Facultad de Medicina
Verified
Journal Article
Open access
PDF file
GFGLORIA ISABEL GUERRERO FONSECA
GLORIA ISABEL GUERRERO FONSECA
BCBrigith Carbajal-Lévano
Brigith Carbajal-Lévano
ARAldo Rojas-Neyra
Aldo Rojas-Neyra
APAstrid Poma-Acevedo
Astrid Poma-Acevedo
FYFreddy Ricardo Ygnacio
Freddy Ricardo Ygnacio
MFManolo Fernández-Díaz
Manolo Fernández-Díaz
Introduction. Oncolytic virotherapy has emerged as a novel method for treating cancer. The newcastle disease virus (ndv) exhibits oncolytic potential and selectively replicates in tumor cells. Human prostate and renal cancer are the leading causes of death worldwide. Objective. To evaluate the oncolytic activity of the rLS1 viral construct on prostate carcinoma (DU-145) and renal cancer (786-O) cell lines, as well as its selective replication in both tumor lines and the non-tumoral madin-darby canine kidney (MDCK) cell line. Methods. The oncolytic effectiveness was determined by reducing cell viability and apoptosis using the (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2h-tetrazolium) MTS colorimetric assay and by labeling with annexin v/anxa5-pe/sytox blue dead cell, respectively. The viral replicative selectivity in cells was evaluated by crystal violet staining. Results. The MTS assay determined that rls1 significantly reduced viability (p < 0,001) in both tumor cell lines without causing a significant reduction in the viability of MDCK cells compared to uninfected cells. A significant increase (p < 0,001) in the percentage of apoptotic cells was observed in 786-O and DU-145 cells infected with rLS1 compared to uninfected cells. Conclusion. The results indicate that rLS1 demonstrated selective oncolytic potential in human prostate and renal cancer cells, suggesting its potential as an antitumoral agent.

14 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
ARAldo Rojas-Neyra
Aldo Rojas-Neyra
Katherine Ivette Calderón MayoKatherine Ivette Calderón Mayo
Katherine Ivette Calderón Mayo
BCBrigith Carbajal-Lévano
Brigith Carbajal-Lévano
GFGLORIA ISABEL GUERRERO FONSECA
GLORIA ISABEL GUERRERO FONSECA
GRGisela Isasi Rivas
Gisela Isasi Rivas
MFManolo Fernandez
Manolo Fernandez
Background/Objectives: Prostate cancer is the second most common type of cancer diagnosed in men. Various treatments for this cancer, such as radiation therapy, surgery, and systemic therapy, can cause side effects in patients; therefore, there is a need to develop new treatment alternatives. One promising approach is virotherapy, which involves using oncolytic viruses (OVs), such as the recombinant Newcastle disease virus (rNDV). Methods: We used the lentogenic rNDV rLS1 strain (the control virus) as our backbone to develop two highly fusogenic rNDVs: rFLCF5nt (the parental virus) and rFLCF5nt-IFN-γ (rFLCF5nt expressing human interferon-gamma (IFN-γ)). We evaluated their oncolytic properties in a prostate cancer cell line (DU145). Results: The results showed the expression and stability of the IFN-γ protein, as confirmed using Western blotting after ten passages in specific pathogen-free chicken embryo eggs using the IFN-γ-expressing virus. Additionally, we detected a significantly high oncolytic activity in DU145 cells infected with the parental virus or the IFN-γ-expressing virus using MTS (a cell viability assay) and Annexin V-PE assays compared with the control virus (p < 0.0001 for both). Conclusions: In conclusion, our data show that IFN-γ-expressing virus can decrease cell viability and induce apoptosis in human prostate cancer in vitro.

8 August 2026 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
YSYacory Sernaque-Aguilar
Yacory Sernaque-Aguilar
DRDora Rios-Matos
Dora Rios-Matos
APAstrid Poma-Acevedo
Astrid Poma-Acevedo
AZAlen Zimic-Sheen
Alen Zimic-Sheen
MBMaría Belén-Balta
María Belén-Balta
MZMirko Zimic
Mirko Zimic
Background: Microagglutination is a sensitive, rapid, and cost-effective serological assay widely used for disease diagnosis and surveillance in animals and humans. However, it traditionally relies on culturing live pathogenic bacteria as antigens, posing biosafety risks and limiting its application primarily to bacterial pathogens. Bacterial surface display technology offers a promising alternative by enabling the presentation of heterologous proteins or peptides on the bacterial surface, avoiding the need to culture the target pathogen, simplifying antigen preparation, and enabling potential diagnostic applications for non-bacterial pathogens. Despite these advantages, integration of this technology with slide-based microagglutination assays has not yet been evaluated. In this proof-of-concept, we evaluated a surface display platform in attenuated Salmonella Enteritidis for antibody detection by slide microagglutination, using the nucleocapsid (N) protein of Infectious Bronchitis Virus (IBV) as a model antigen. Results: The IBV N protein was fused to the N-terminal anchor domain of the ice nucleation protein (INP) and cloned into pET-28a. The resulting INP_N fusion protein was expressed in attenuated Salmonella Enteritidis, and its surface exposure was evaluated by immunofluorescence and flow cytometry on non-permeabilized cells, with flow cytometry indicating a surface display efficiency of 96.5%. Slide microagglutination was performed using 50 hen sera and inactivated Salmonella Enteritidis cells presenting surface-exposed N protein. This assay identified all positive sera and 20 of 25 negative sera, showing substantial agreement with the reference ELISA (κ = 0.8), with preliminary estimates of 100% sensitivity (95% CI, 87–100%) and 80% specificity (95% CI, 61–91%). No cross-reactivity was observed with commercial antisera against pathogens unrelated to IBV. Conclusions: The attenuated Salmonella surface-display platform integrated into a slide microagglutination assay showed preliminary feasibility for antibody detection under the conditions evaluated. This approach does not require live pathogen cultivation, specialized equipment, antigen purification, or chemical conjugation steps. However, further optimization is needed to improve the platform’s display efficiency and enhance specificity without compromising sensitivity. In addition, evaluation using a larger and more diverse sample set, including field samples, is required to further assess the performance and potential applicability of the assay.